Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (51-60 of 519) with videos related to

Pageof 52
Sort By:
Cancer Treatment and Research|October 4, 2016
MGUS and Smoldering Multiple Myeloma: Diagnosis and EpidemiologyMaría-Victoria Mateos, Ola Landgren
Blood|October 10, 2014
How I treat smoldering multiple myelomaIrene M Ghobrial, Ola Landgren
Seminars in Hematology|February 24, 2026
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical managementOla Landgren, Rafat Abonour, Dickran Kazandjian
Leukemia & Lymphoma|January 26, 2011
Associations between multiple myeloma and other malignanciesOla Landgren, Aaron Polliack, Tamar Tadmor
Leukemia & Lymphoma|September 5, 2022
T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscapeDickran Kazandjian, Andrew Kowalski, Ola Landgren
The New England Journal of Medicine|May 11, 2012
Bortezomib to treat the TEMPI syndromeMary Kwok, Neha Korde, Ola Landgren
The New England Journal of Medicine|December 14, 2011
Myeloma and second primary cancersOla Landgren, Anish Thomas, Sham Mailankody
The New England Journal of Medicine|December 30, 2025
Monoclonal Gammopathy of Undetermined SignificanceMajdolen Istaiti, Ola Landgren, Ari Zimran
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
The road to treating smoldering multiple myelomaNeha Korde, Sham Mailankody, Ola Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disordersGary A Ulaner, C Ola Landgren
Pageof 52

Showing results (51-60 of 519) with videos related to

Sort By:
Pageof 52
Cancer Treatment and Research|October 4, 2016
MGUS and Smoldering Multiple Myeloma: Diagnosis and EpidemiologyMaría-Victoria Mateos, Ola Landgren
Blood|October 10, 2014
How I treat smoldering multiple myelomaIrene M Ghobrial, Ola Landgren
Seminars in Hematology|February 24, 2026
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical managementOla Landgren, Rafat Abonour, Dickran Kazandjian
Leukemia & Lymphoma|January 26, 2011
Associations between multiple myeloma and other malignanciesOla Landgren, Aaron Polliack, Tamar Tadmor
Leukemia & Lymphoma|September 5, 2022
T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscapeDickran Kazandjian, Andrew Kowalski, Ola Landgren
The New England Journal of Medicine|May 11, 2012
Bortezomib to treat the TEMPI syndromeMary Kwok, Neha Korde, Ola Landgren
The New England Journal of Medicine|December 14, 2011
Myeloma and second primary cancersOla Landgren, Anish Thomas, Sham Mailankody
The New England Journal of Medicine|December 30, 2025
Monoclonal Gammopathy of Undetermined SignificanceMajdolen Istaiti, Ola Landgren, Ari Zimran
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
The road to treating smoldering multiple myelomaNeha Korde, Sham Mailankody, Ola Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disordersGary A Ulaner, C Ola Landgren
Pageof 52